Reactions to Allergy Shots: How Patterns Change Across Treatment
Reactions to allergy shots follow predictable patterns. Build-up carries the highest per-injection systemic reaction rate; cluster protocols run 3x higher than conventional (Tversky 2022). Reactions spike at vial transitions and pollen season. Recurrent large local reactions are associated with 41.7% systemic reaction rate versus 10.7% without (Calabria 2011). For most patients, frequency decreases in maintenance as IgG4 antibodies rise.
8 peer-reviewed sources
Reactions to allergy shots are most frequent during dose escalation in build-up, spike at new-vial transitions and pollen season, and typically decrease over time in maintenance as immune tolerance develops.
Key facts
A 2026 observational cohort of 2,897 patients on at-home sublingual immunotherapy reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, showing how benefit accrues with time on treatment rather than arriving early.
Your Reaction History Across 3-5 Years of Allergy Shots
If you have been getting allergy shots for a while and have had multiple reactions — or you are about to start and want to know what to expect over time — this page takes the longitudinal view. Rather than focusing on any single reaction event, it explains how reaction patterns evolve across the full treatment course from early build-up to established maintenance.
Reaction frequency and severity are not random. They follow the pharmacology and immunology of dose escalation: reactions are more common early in treatment when doses are escalating into unknown territory; they tend to concentrate around transition points (new vials, accelerated schedules, pollen seasons); and for most patients, they decrease as IgG4 blocking antibodies rise and immune tolerance develops.
Understanding this pattern is clinically important for two reasons. First, it helps patients contextualize their experience — a reaction during build-up does not necessarily predict how maintenance will go. Second, the pattern itself is a signal: recurring large local reactions in the same patient, or systemic reactions at multiple visits, change the clinical calculus and should prompt a conversation about dose modification, premedication, or whether SCIT is the right treatment modality.
Before beginning any immunotherapy, identifying your allergen sensitization profile through comprehensive allergy testing — services like Curex offer at-home testing covering 40+ allergens — provides the baseline data that informs extract composition and dosing strategy throughout treatment.
Build-up carries the highest per-injection reaction rate; 59% of SCIT fatalities occur during maintenance at vial transitions. A pattern of recurrent large local reactions predicts higher systemic reaction risk (41.7% vs 10.7% in non-LLR patients). Reaction frequency typically decreases in maintenance.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex at-home allergy shots are clinician-supervised; confirm your current program quote before enrolling.
Join the waitlistCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
SCIT vs. SLIT: Reaction Pattern Comparison Over Time
For patients whose reaction pattern suggests poor injection tolerance — recurrent large local reactions, multiple systemic reactions despite dose adjustment, or inability to escalate due to persistent reactions — sublingual immunotherapy offers the same desensitization through a route with substantially lower systemic reaction rates. Unlike SCIT, SLIT does not have the same vial-transition, pollen-season, and exercise-cofactor dynamics that produce reaction spikes in the subcutaneous route.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT, Curex)Best | Strong efficacy evidence; efficacy increases with reaching maintenance dose and completing 3-5 years | 3-5 years | $3,000-10,000 | Self-administered at home with Curex; reaction-pattern monitoring, vial-transition and seasonal dose adjustments handled by your care team with changes to a new vial or concentration supervised live in the Virtual Shot Room | Reaction patterns vary: build-up highest rate, maintenance has fatal concentration at transitions |
Sublingual Drops (SLIT) | Comparable symptom reduction; significantly fewer adverse events (RR 0.17 vs SCIT in pediatric meta-analysis) | 3-5 years | $2,340-3,500 | Daily at-home dosing; no vial-transition reactions; no in-clinic observation requirement | No confirmed fatalities worldwide; systemic reactions much lower; no injection-site LLR pattern |
Antihistamines (daily) | Symptom management only; no pattern of increasing tolerance over time | Indefinite | $750-2,500 | Daily pill | No reaction patterns to monitor |
- Efficacy
- Strong efficacy evidence; efficacy increases with reaching maintenance dose and completing 3-5 years
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-10,000
- Convenience
- Self-administered at home with Curex; reaction-pattern monitoring, vial-transition and seasonal dose adjustments handled by your care team with changes to a new vial or concentration supervised live in the Virtual Shot Room
- Safety
- Reaction patterns vary: build-up highest rate, maintenance has fatal concentration at transitions
- Efficacy
- Comparable symptom reduction; significantly fewer adverse events (RR 0.17 vs SCIT in pediatric meta-analysis)
- Duration
- 3-5 years
- Cost (5yr)
- $2,340-3,500
- Convenience
- Daily at-home dosing; no vial-transition reactions; no in-clinic observation requirement
- Safety
- No confirmed fatalities worldwide; systemic reactions much lower; no injection-site LLR pattern
- Efficacy
- Symptom management only; no pattern of increasing tolerance over time
- Duration
- Indefinite
- Cost (5yr)
- $750-2,500
- Convenience
- Daily pill
- Safety
- No reaction patterns to monitor
If your reaction pattern — recurrent large local reactions, systemic events despite dose adjustment, or trouble tolerating injection escalation — has made clinic SCIT hard to sustain, Curex delivers the same subcutaneous immunotherapy as one weekly at-home shot with pricing confirmed in a current program quote, with gradual week-by-week dose escalation, the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on hand before you start, and board-certified allergist oversight of your dose-adjustment plan.
Join the waitlistReaction Patterns Across the Treatment Timeline
Local injection-site reactions — redness, swelling, and itching at the shot location — occur in 30 to 80% of allergy shot patients and are considered a normal expected part of treatment. Systemic reactions (affecting the whole body) occur in approximately 0.1 to 0.2% of injection visits. These overall rates, however, mask important variation across the treatment course: the per-injection risk changes substantially depending on where you are in treatment, which vial you are on, and what season it is. The most important risk-pattern insight from the AAAAI/ACAAI National Surveillance Study (Epstein 2019, covering 54 million injection visits): a prior systemic reaction is the strongest individual-level predictor of future systemic reactions, conferring a 4-fold higher rate of subsequent events (Roy 2007). If you have had one systemic reaction, your trajectory is different from a patient who has had none — and your allergist should be adjusting your protocol accordingly. For context on the baseline risk, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found a systemic reaction rate of just 0.16% per patient across 23,614 patients giving 2,021,600 injections, with no fatalities — lower than the 3% to 14% typically reported with office-based shots.
During build-up, each injection escalates the dose into previously uncharted territory for your immune system. Per-injection systemic reaction rates are higher in this phase than maintenance — driven by dose escalation before sufficient IgG4 blocking antibodies have formed. Most reactions are local or Grade 1 systemic (cutaneous/upper respiratory). Conventional build-up (once weekly over 3-6 months) is safer than accelerated schedules: cluster protocols carry approximately 3-fold higher per-injection systemic reaction rates (Tversky 2022, 0.69% conventional vs 2.29% cluster; IRR 3.3, 95% CI 1.5-7.3).
Report any systemic reaction immediately. Your clinic should document every reaction and use that data to guide the pace of dose escalation. If you are on a cluster schedule and experiencing frequent reactions, discuss switching to a conventional schedule with your allergist.
While a single large local reaction (LLR) does not reliably predict future systemic events, a pattern of recurring LLRs at the same site across multiple visits tells a different story. The REPEAT Study (Calabria 2011, Ann Allergy) found that patients with frequent recurrent LLRs experienced at least one systemic reaction in 41.7% of cases over follow-up, compared to 10.7% of non-LLR patients. Roy 2007 found that approximately one-third of systemic reactions were preceded by LLRs. Pre-medication with antihistamines can reduce LLR size by 30-50% without affecting treatment efficacy.
Track and report LLR size and duration at every visit. Your allergist may add pre-injection antihistamine, reduce dose at each visit, or modify the escalation schedule. A pattern of recurrent LLRs warrants active dose management — not dismissal.
Two predictable reaction spike points occur during otherwise-stable maintenance. New-vial transitions carry elevated reaction risk because fresh allergen extract concentrate may have higher biological potency than the previous vial's final doses. The 2011 Practice Parameter recommends a 50% dose reduction at every new vial. Counterintuitively, 59% of SCIT fatalities in the Bernstein 2004 survey occurred during the maintenance phase, often in association with new-vial transitions. Pollen season overlap primes tissue mast cells through repeated environmental exposure, lowering the threshold for systemic reactions at previously tolerated maintenance doses. Year 3 surveillance (Epstein 2013) found practices that always reduced doses during peak season had 44% Grade 2/3 systemic reactions versus 65% in practices that did not (P=0.04).
Your allergist should automatically reduce your dose by 50% when opening a new vial. If they do not mention it, ask. Discuss peak-season dose reduction with your allergist if you are sensitized to pollen allergens. Report any new reaction after a vial change immediately.
A prior systemic reaction is the strongest individual predictor of future systemic reactions. Roy 2007 found a 4-fold higher rate of subsequent systemic reactions in patients with prior SR history. Matloff 1993 found that 45% of patients who had a systemic reaction had a prior SR. After a Grade 1 SR, the standard protocol is to reduce the dose to approximately 50% of the reaction-causing dose. After Grade 2: reduce to approximately 10% of the reaction-causing dose. After Grade 3: 10-fold dilution with formal reconsideration of continuing SCIT. These dose-reduction protocols are not universally standardized but represent the consensus guidance in the 2011 Practice Parameter.
After any systemic reaction, dose must be reduced before resuming. Document the grade, timing, and dose at which the reaction occurred. Your allergist should use this data to determine whether to continue, modify, or discontinue SCIT. Multiple Grade 2+ systemic reactions despite dose modification may indicate that SCIT is not the appropriate modality for you.
When to Worry: Decision Guide
Have you experienced large local reactions at multiple consecutive visits?
Recurrent LLR pattern — discuss with allergist
Report pattern to your allergist. Ask about antihistamine premedication, dose reduction, or modified escalation schedule. REPEAT Study data (Calabria 2011) supports active management of recurrent LLR patterns.
No recurrent LLR pattern
Proceed to assess systemic reaction history.
Have you had a prior systemic reaction to allergy shots?
Higher-risk patient — requires adjusted protocol
Ensure your allergist has adjusted the dose protocol after the systemic reaction. Discuss peak-season dose reduction and new-vial reduction. Consider extended observation windows if reactions have been delayed-onset.
No prior systemic reactions
Continue monitoring. Report any large local reactions (over 2.5 cm) before next dose. Watch for reaction spikes at new-vial transitions and during pollen season.
Frequently asked questions
Do allergy shot reactions get worse over time?
For most patients, reactions to allergy shots decrease in frequency and severity as treatment progresses. During build-up, each dose escalation is new territory for the immune system, producing higher per-injection reaction rates. As IgG4 blocking antibodies rise — increasing 10 to 100-fold during SCIT treatment (Aalberse et al. 2009) — the immune response to each dose becomes more controlled. However, reactions can spike at predictable transition points regardless of how long a patient has been in treatment: new-vial changes carry elevated reaction risk (50% dose reduction is recommended), and pollen season overlap primes tissue mast cells to respond more intensely to previously tolerated maintenance doses. A prior systemic reaction is the strongest predictor of future systemic reactions (Roy 2007, 4-fold increased rate).
What does it mean if I keep getting large local reactions to allergy shots?
Recurrent large local reactions (LLRs) — swelling larger than a quarter (2.5 cm) at the injection site across multiple visits — are a clinically important pattern that warrants active management. While a single LLR does not predict systemic reactions (Tankersley 2000), the REPEAT Study (Calabria 2011, Ann Allergy) found that patients with frequent recurrent LLRs experienced at least one systemic reaction in 41.7% of cases, compared to 10.7% of non-LLR patients. If you are consistently getting large local reactions, discuss these options with your allergist: antihistamine premedication before each injection (can reduce LLR size by 30-50%), dose reduction at each escalation step, or modified escalation schedule. Documenting the size and timing of each LLR gives your allergist the data needed to make these decisions.
Why did I have a reaction to my allergy shot after months of no reactions?
Late reactions after a period of uneventful injections are most commonly associated with new-vial transitions or pollen-season overlap. When a new vial of allergen extract is opened, the fresh concentrate may have higher biological potency than the end of the previous vial, triggering a stronger reaction at the same dose. The AAAAI/ACAAI Practice Parameter recommends a 50% dose reduction at every new vial specifically because of this risk. During peak pollen season, repeated environmental allergen exposure primes tissue mast cells, lowering the systemic reaction threshold for your maintenance dose. Counterintuitively, 59% of SCIT fatalities occurred during the maintenance phase (Bernstein 2004), concentrated around these transition moments — which is why consistent dose adjustment protocols matter even for long-established patients.
How does my allergist decide to adjust my dose after a reaction?
Dose adjustment after a systemic reaction follows a protocol graded by reaction severity, though no universally standardized schedule exists. The 2011 AAAAI/ACAAI Practice Parameter provides common conventions: after a Grade 1 systemic reaction, the dose is typically reduced to approximately 50% of the reaction-causing dose (or one step back). After a Grade 2 systemic reaction, the dose is reduced to approximately 10% of the reaction-causing dose (two to three dilution steps back). After a Grade 3 systemic reaction, a 10-fold dilution is recommended, with formal reconsideration of whether to continue SCIT. These reductions apply to the starting point for the next dose escalation — the patient then re-escalates from that lower starting point. New-vial transitions also call for a 50% dose reduction regardless of prior reactions.
Is a reaction during allergy shot build-up different from a maintenance reaction?
Yes, both in mechanism and statistical profile. Build-up reactions are driven by dose escalation into territory where IgG4 blocking antibodies have not yet developed to compete with IgE for allergen binding. They tend to be more frequent per injection but are usually mild to moderate. Maintenance reactions are driven by specific transition events — new vials with fresh concentrate, pollen-season priming, or cofactors like exercise or uncontrolled asthma — rather than systematic dose escalation. Maintenance fatalities, counterintuitively, outnumber build-up fatalities (59% vs 41% per Bernstein 2004) despite a lower baseline per-injection systemic reaction rate. The risk in maintenance is concentrated at predictable moments, which is why dose-adjustment protocols for vial changes and seasonal reductions exist specifically for patients.
How does pollen season affect allergy shot reactions?
During your relevant pollen season, your body is simultaneously receiving environmental allergen through mucous membranes and injected allergen through your allergy shots. Environmental exposure upregulates tissue mast cell density, eosinophil infiltration, and adhesion molecule expression — effectively priming your immune system to respond more intensely to the same injected dose that had been uneventful in winter. This summation effect is supported by historical fatality data (Lockey 1987): 41% of SCIT fatalities occurred during the patient's relevant pollen season. Year 3 surveillance (Epstein 2013, Ann Allergy) found that practices consistently applying peak-season dose reduction had significantly fewer Grade 2/3 systemic reactions — 44% versus 65% in practices that did not reduce doses (P=0.04). Standard practice is a 50% dose reduction during peak season for highly sensitized patients.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreAllergy Injection Reactions: All Modalities Compared | Curex
Allergy injection reactions: SCIT 0.1%, cluster 2.3%, venom IT 5-15%. Compare reaction profiles across SCIT, rush, VIT, and ILIT modalities.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT retrains the immune system over 3–5 years and is the only disease-modifying allergy treatment; many patients get long-term relief that can persist after treatment.
Read moreAdverse Reactions to Allergy Shots | SCIT Guide | Curex
Adverse reactions to allergy shots classified by WAO grading (Cox 2010): local vs systemic, immediate vs delayed, Grade 1-5 incidence rates and reporting.
Read moreSystemic Reactions to Allergy Shots: WAO Grades 1-5 | Curex
Systemic reactions to allergy shots: WAO Grade 1 (74% of events) through Grade 5 (1/9M visits). Pathophysiology, onset timing, and management protocols.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.